Spyral htn-on med study demonstrates meaningful clinical benefits consistent with other spyral htn renal denervation trials

Dublin and chicago , nov. 7, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced the six-month results from the full cohort of the spyral htn-on med clinical trial. the data were presented today as late-breaking clinical science at the american heart association (aha) scientific sessions 2022.
MDT Ratings Summary
MDT Quant Ranking